These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 1498450)
1. Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy. Martin RB; Fisher ME; Minchin RF; Teo KL Math Biosci; 1992 Jul; 110(2):201-19. PubMed ID: 1498450 [TBL] [Abstract][Full Text] [Related]
2. Low-intensity combination chemotherapy maximizes host survival time for tumors containing drug-resistant cells. Martin RB; Fisher ME; Minchin RF; Teo KL Math Biosci; 1992 Jul; 110(2):221-52. PubMed ID: 1498451 [TBL] [Abstract][Full Text] [Related]
3. Conflicting objectives in chemotherapy with drug resistance. Costa MI; Boldrini JL Bull Math Biol; 1997 Jul; 59(4):707-24. PubMed ID: 9214850 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity. Costa MI; Boldrini JL; Bassanezi RC Math Biosci; 1995 Feb; 125(2):211-28. PubMed ID: 7881195 [TBL] [Abstract][Full Text] [Related]
5. Drug kinetics and drug resistance in optimal chemotherapy. Costa MI; Boldrini JL; Bassanezi RC Math Biosci; 1995 Feb; 125(2):191-209. PubMed ID: 7881194 [TBL] [Abstract][Full Text] [Related]
6. Optimal chemotherapy: a case study with drug resistance, saturation effect, and toxicity. Costa MI; Boldrini JL; Bassanezi RC IMA J Math Appl Med Biol; 1994; 11(1):45-59. PubMed ID: 8057040 [TBL] [Abstract][Full Text] [Related]
7. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs. Usher JR; Henderson D IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582 [TBL] [Abstract][Full Text] [Related]
8. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy. Boldrini JL; Costa MI IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031 [TBL] [Abstract][Full Text] [Related]
9. Estimation of tumor cell kill from Gompertz growth curves. Lloyd HH Cancer Chemother Rep; 1975; 59(2 Pt 1):267-77. PubMed ID: 1149006 [TBL] [Abstract][Full Text] [Related]
10. Regrowth resistance in cancer: why has it been largely ignored? Preisler HD; Venugopal P Cell Prolif; 1995 Jun; 28(6):347-56. PubMed ID: 7626689 [TBL] [Abstract][Full Text] [Related]
11. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs. Yoon N; Vander Velde R; Marusyk A; Scott JG Bull Math Biol; 2018 Jul; 80(7):1776-1809. PubMed ID: 29736596 [TBL] [Abstract][Full Text] [Related]
12. A model for metastases formation. Markovitch S Int J Biomed Comput; 1993 Jan; 32(1):19-33. PubMed ID: 8425750 [TBL] [Abstract][Full Text] [Related]
13. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457 [TBL] [Abstract][Full Text] [Related]
14. Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Poirson-Bichat F; Gonçalves RA; Miccoli L; Dutrillaux B; Poupon MF Clin Cancer Res; 2000 Feb; 6(2):643-53. PubMed ID: 10690550 [TBL] [Abstract][Full Text] [Related]
15. [Kinetics of breast neoplasms]. Surbone A; Norton L Minerva Med; 1994; 85(1-2):7-16. PubMed ID: 8152580 [TBL] [Abstract][Full Text] [Related]
16. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Frei E; Richardson P; Avigan D; Bunnell C; Wheeler C; Elias A Bone Marrow Transplant; 1999 Nov; 24(9):939-45. PubMed ID: 10556951 [TBL] [Abstract][Full Text] [Related]
17. A mathematical model of drug resistance: heterogeneous tumors. Panetta JC Math Biosci; 1998 Jan; 147(1):41-61. PubMed ID: 9401351 [TBL] [Abstract][Full Text] [Related]
18. Cancer chemotherapy. Secchi GC Ann Ital Med Int; 1990; 5(3 Pt 3):288-95. PubMed ID: 2081089 [TBL] [Abstract][Full Text] [Related]
19. Evolving concepts in the systemic drug therapy of breast cancer. Norton L Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000 [TBL] [Abstract][Full Text] [Related]
20. A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment. Panetta JC Bull Math Biol; 1996 May; 58(3):425-47. PubMed ID: 8688836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]